Literature DB >> 17559947

Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy.

Amjad A Ilyas1, Zi-Wei Chen.   

Abstract

Elevated levels of anti-GM1 antibodies are associated with motor nerve syndromes. Although there is a lot of circumstantial evidence that anti-GM1 antibodies may be causing the disease, their precise role remains unclear. In order to study the role of anti-GM1 antibodies in the pathogenesis of peripheral neuropathy, eight Lewis rats were injected with GM1 ganglioside mixed with keyhole limpet hemocyanin (KLH) and emulsified with Freund's adjuvant and three rats were immunized with GM1 in liposomes. Although IgM class anti-GM1 antibodies were detected in all animals immunized with GM1, none of the animals exhibited overt signs of neuropathy during 6 months after initial immunization. IgG antibody to GM1 was not produced in any of the animals. There was no pathological evidence of nerve damage. These studies suggest that elevated levels of IgM anti-GM1 antibodies by themselves do not cause nerve damage in rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559947      PMCID: PMC2705978          DOI: 10.1016/j.jneuroim.2007.05.004

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  45 in total

1.  High affinity of anti-GM1 antibodies is associated with disease onset in experimental neuropathy.

Authors:  Romina Comín; Nobuhiro Yuki; Pablo H H Lopez; Gustavo A Nores
Journal:  J Neurosci Res       Date:  2006-10       Impact factor: 4.164

2.  The rabbit CD1 and the evolutionary conservation of the CD1 gene family.

Authors:  F Calabi; K T Belt; C Y Yu; A Bradbury; W J Mandy; C Milstein
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

3.  Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy.

Authors:  H Baba; G C Daune; A A Ilyas; A Pestronk; D R Cornblath; V Chaudhry; J W Griffin; R H Quarles
Journal:  J Neuroimmunol       Date:  1989-12       Impact factor: 3.478

4.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.

Authors:  A Pestronk; D R Cornblath; A A Ilyas; H Baba; R H Quarles; J W Griffin; K Alderson; R N Adams
Journal:  Ann Neurol       Date:  1988-07       Impact factor: 10.422

5.  Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier.

Authors:  F P Thomas; W Trojaborg; C Nagy; M Santoro; S A Sadiq; N Latov; A P Hays
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

6.  Serum antibodies to gangliosides in Guillain-Barré syndrome.

Authors:  A A Ilyas; H J Willison; R H Quarles; F B Jungalwala; D R Cornblath; B D Trapp; D E Griffin; J W Griffin; G M McKhann
Journal:  Ann Neurol       Date:  1988-05       Impact factor: 10.422

7.  Anti-MAG IgM paraproteins from some patients with polyneuropathy associated with IgM paraproteinemia also react with sulfatide.

Authors:  A A Ilyas; S D Cook; M C Dalakas; F A Mithen
Journal:  J Neuroimmunol       Date:  1992-03       Impact factor: 3.478

8.  IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside.

Authors:  A A Ilyas; R H Quarles; T D MacIntosh; M J Dobersen; B D Trapp; M C Dalakas; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies.

Authors:  A Pestronk; V Chaudhry; E L Feldman; J W Griffin; D R Cornblath; E H Denys; M Glasberg; R W Kuncl; R K Olney; W C Yee
Journal:  Ann Neurol       Date:  1990-03       Impact factor: 10.422

10.  Identification and characterization of gangliosides reacting with IgM paraproteins in three patients with neuropathy associated with biclonal gammopathy.

Authors:  A A Ilyas; H J Willison; M C Dalakas; J N Whitaker; R H Quarles
Journal:  J Neurochem       Date:  1988-09       Impact factor: 5.372

View more
  4 in total

Review 1.  Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Authors:  Jens O Watzlawik; Bharath Wootla; Meghan M Painter; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

2.  Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies.

Authors:  John W Rumsey; Case Lorance; Max Jackson; Trevor Sasserath; Christopher W McAleer; Christopher J Long; Arindom Goswami; Melissa A Russo; Shruti M Raja; Karissa L Gable; Doug Emmett; Lisa D Hobson-Webb; Manisha Chopra; James F Howard; Jeffrey T Guptill; Michael J Storek; Miguel Alonso-Alonso; Nazem Atassi; Sandip Panicker; Graham Parry; Timothy Hammond; James J Hickman
Journal:  Adv Ther (Weinh)       Date:  2022-04-05

3.  An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome.

Authors:  Kazim A Sheikh; Gang Zhang
Journal:  F1000 Biol Rep       Date:  2010-03-25

4.  Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG.

Authors:  A A Ilyas; Y Gu; M C Dalakas; R H Quarles; S Bhatt
Journal:  J Neuroimmunol       Date:  2007-11-26       Impact factor: 3.478

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.